| Name | Title | Contact Details |
|---|
Founded in 2004, Rapid Pathogen Screening is an emerging developer, manufacturer, and marketer of rapid point-of-care (POC) diagnostic tests. The company’s innovative and patented technology platform facilitates the development of a spectrum of cost-effective tests to rapidly identify patients with infectious diseases and inflammatory conditions. As a result of U.S. government contracts, this platform is also being used to develop tests for bio-terrorism and chemical nerve agent blood toxins. RPS tests have high sensitivity and specificity, and can be easily performed by a clinician or their staff without extensive training or additional equipment.
Rapid, Personalized T-cell Therapies for Cancer on BlueSphere Bio…
Conagen is a #syntheticbiology leader, supporting our global partners through #enzymatic and #microbial platforms and #biomanufacturing capabilities.
Protea Biosciences is a Morgantown, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ikena Oncology is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients.